The instant invention provides an economical flow-through method for determining amount of target proteins in a sample. An antibody preparation (whether polyclonal or monoclonal, or any equivalent specific binding agent) is used to capture and thus enrich a specific monitor peptide (a specific peptide fragment of a protein to be quantitated in a proteolytic digest of a complex protein sample) and an internal standard peptide (the same chemical structure but including stable isotope labels). Upon elution into a suitable mass spectrometer, the natural (sample derived) and internal standard (isotope labeled) peptides are quantitated, and their measured abundance ratio used to calculate the abundance of the monitor peptide, and its parent protein, in the initial sample.

Methods of detecting a target in a sample are provided. Kits for performing the methods described herein are also provided.

Methods of detecting a target in a sample are provided. Kits for performing the methods described herein are also provided.

Methods of circulating Fatty Acid Synthase (cFAS) detection, assays, and kits thereof, as well as methods of diagnosis and treatment for cardiovascular-related diseases based on cFAS are provided. Exemplary embodiments of the methods, assays, and kits disclosed herein allow for improved, noninvasive, low-cost, and reliable diagnosis and treatment for cardiovascular-related diseases, particularly in subjects suffering from both symptomatic and asymptomatic Peripheral Arterial Disease (PAD), via detecting and measuring cFAS from LDL-associated cFAS captured from a biological sample.

Methods of circulating Fatty Acid Synthase (cFAS) detection, assays, and kits thereof, as well as methods of diagnosis and treatment for cardiovascular-related diseases based on cFAS are provided. Exemplary embodiments of the methods, assays, and kits disclosed herein allow for improved, noninvasive, low-cost, and reliable diagnosis and treatment for cardiovascular-related diseases, particularly in subjects suffering from both symptomatic and asymptomatic Peripheral Arterial Disease (PAD), via detecting and measuring cFAS from LDL-associated cFAS captured from a biological sample.

Methods of detecting a target in a sample are provided. Kits for performing the methods described herein are also provided.

Methods of detecting a target in a sample are provided. Kits for performing the methods described herein are also provided.

The present disclosure relates to the field of proteomics. More specifically, the present disclosure provides compositions and methods for molecular indexing of proteins by self-assembly. In one aspect, the present disclosure provides a library of self-assembled protein-DNA conjugates. In particular embodiments, each protein-DNA conjugate comprises (a) a cDNA comprising a barcode, wherein the cDNA is conjugated with a ligand that specifically binds a polypeptide tag; and (b) a fusion protein comprising the polypeptide tag and a protein of interest, wherein the ligand is covalently bound to the polypeptide tag.

The present disclosure relates to the field of proteomics. More specifically, the present disclosure provides compositions and methods for molecular indexing of proteins by self-assembly. In one aspect, the present disclosure provides a library of self-assembled protein-DNA conjugates. In particular embodiments, each protein-DNA conjugate comprises (a) a cDNA comprising a barcode, wherein the cDNA is conjugated with a ligand that specifically binds a polypeptide tag; and (b) a fusion protein comprising the polypeptide tag and a protein of interest, wherein the ligand is covalently bound to the polypeptide tag.

Disclosed in the present invention are a monoclonal antibody (YWHG-4) against HLA-G isoforms (HLA-G1, HLA-G4, HLA-G5) and use thereof. The antibody (YWHG-4) is produced by the hybridoma deposited under CCTCC NO: 2021204, and an antigenic peptide (RGYYNQSEASSHTLQWMIGC) of amino acid sequences at positions 106-126 of a heavy chain of HLA-G molecules is used as an immunogen. Provided in the present invention are a nucleotide encoding the YWHG-4 antibody of the present invention and an encoded amino acid sequence thereof. Further provided in the present invention is use of the YWHG-4 antibody in the detection of the HLA-G isoforms (HLA-G1, HLA-G4, HLA-G5) by means of immunoblotting, immunohistochemistry, ELISA and flow cytometry.